Adamis Pharmaceuticals Corp - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ADMP Nasdaq 2834 http://www.adamispharmaceuticals.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adamis Pharmaceuticals Corp

Adamis Pharmaceuticals Announces Pre-IND Feedback from FDA Enabling Advancement of Tempol, a Novel Anti-Inflammatory and Anti-Oxidant Drug for the Treatment of COVID-19 - Aug 14th, 2020 1:00 pm
Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release - Aug 6th, 2020 4:30 pm
Adamis Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement - Aug 5th, 2020 8:05 pm
Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock? - Jul 23rd, 2020 1:00 pm
Adamis Pharmaceuticals Provides Update on SYMJEPI Products - Jul 1st, 2020 1:00 pm
Adamis Pharmaceuticals Announces Publication of Pharmacokinetic model suggesting that higher doses of naloxone are needed for successful resuscitation due to fentanyl overdose - Jun 18th, 2020 1:00 pm
Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19 - Jun 15th, 2020 1:00 pm
Adamis Pharmaceuticals Announces Publication of Pharmacokinetic study comparing ZIMHI to current 2 mg intramuscular dose of naloxone - May 27th, 2020 1:00 pm
Edited Transcript of ADMP earnings conference call or presentation 18-May-20 9:00pm GMT - May 25th, 2020 2:37 pm
Adamis Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update - May 18th, 2020 8:35 pm
Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA - May 18th, 2020 1:00 pm
The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings - May 12th, 2020 12:06 pm
Adamis Pharmaceuticals Provides Update on SYMJEPI Products and Announces Distribution and Commercialization Agreement for SYMJEPI and ZIMHI Products - May 12th, 2020 12:35 am
Adamis (ADMP) Moves to Strong Buy: Rationale Behind the Upgrade - Apr 29th, 2020 4:00 pm
Adamis Pharmaceuticals Announces Publication Demonstrating PET Scan Results of Higher Dose Naloxone in Monkeys - Apr 23rd, 2020 1:00 pm
Adamis Pharmaceuticals Announces Production of Additional Drugs by its US Compounding Subsidiary to Aid in the COVID-19 Pandemic - Apr 21st, 2020 1:00 pm
Adamis Pharmaceuticals Announces Receipt of Loan Proceeds Under Paycheck Protection Program - Apr 15th, 2020 8:05 pm
Adamis Pharmaceuticals Announces Production of Products by its Subsidiary US Compounding to Aid in the COVID-19 Pandemic - Apr 1st, 2020 1:00 pm
Adamis Pharmaceuticals Announces 2019 Financial Results and Business Update - Mar 30th, 2020 8:40 pm
Adamis Pharmaceuticals Announces Pricing of $6.7 Million Registered Direct Offering - Feb 21st, 2020 2:15 pm